Three 2026 Breakthrough Prize winners reflect on developing Luxturna, a gene therapy that treats blindness caused by rare ...
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...
Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...
More than four years after the last of four boys died in a troubled Phase I/II trial of a gene therapy candidate for X-linked Myotubular Myopathy (XLMTM), Astellas Gene Therapies says it remains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results